In a report issued on July 9, Jason McCarthy from Maxim Group maintained a Buy rating on Abeona Therapeutics (ABEO), with a price target of $14. The company’s shares closed yesterday at $4.29, close to its 52-week low of $4.16.
According to TipRanks.com, McCarthy is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -18.4% and a 26.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Aridis Pharmaceuticals Inc, and Achieve Life Sciences Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Abeona Therapeutics with a $22.80 average price target, implying a 431.5% upside from current levels. In a report issued on June 26, Mizuho Securities also initiated coverage with a Buy rating on the stock with a $28 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $15.65 and a one-year low of $4.16. Currently, Abeona Therapeutics has an average volume of 588.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.
